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Abstract: Sedation is widely used for auditory brainstem response (ABR) testing for infants or young children who
are unable to sleep or remain adequately quiet for testing. Because chloral hydrate is no longer readily available,
dexmedetomidine has been proposed as an alternative medicinal agent to achieve moderate levels of sedation without
risk of respiratory depression. The purpose of the study was to assess the effectiveness of dexmedetomidine in terms
of the completeness of the audiologic data obtained in achieving moderate levels of sedation for auditory brainstem
response testing. A retrospective chart review was conducted on 99 patients at Kennedy Krieger Institute. Participants
were administered either chloral hydrate or dexmedetomidine prior to ABR testing. Effectiveness was defined as
having obtained thresholds for click and tone burst stimuli centered at 500, 2000, and 4000 Hz for both ears. Complete
audiological data were obtained on 92.2% of patients sedated with dexmedetomidine whereas complete audiological data
were obtained on 91% of patients sedated with choral hydrate in a period prior to the use of dexmedetomidine. It was
concluded that dexmedetomidine is as effective as chloral hydrate in producing an appropriate state for sedated auditory
brainstem response testing.
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Introduction
The auditory brainstem response (ABR) is used to
delineate the auditory status of infants and children who
are unwilling or unable to cooperate for developmentally
appropriate behavioral test procedures or to confirm
behavioral test findings obtained when a hearing loss is
suspected. ABRs are bioelectric signals generated by
the auditory nerve and units in the brainstem in response
to auditory stimuli. The ABR is an onset response and
requires neural synchrony in order to effectively record a
response from electrodes which are placed on the scalp.
ABR testing is a non-invasive procedure but requires the
patient to remain quiet and relaxed for approximately 45
to 60 minutes. Sedation is widely used to complete ABR
testing for children who are not able to sleep naturally
or remain sufficiently quiet for the duration of testing
(American Academy of Audiology, 2012). Infants and

older children with developmental disabilities, behavior
disorder, autism, or intellectual disabilities often require
sedation for successful completion of ABR testing. Using
general anesthesia will achieve an adequate state for
testing; however, the testing facility must arrange for
anesthesiology, which may introduce delays in early
identification of hearing loss. Consequently, use of
sedation or general anesthesia could compromise
adherence with Joint Committee on Infant Hearing
Guidelines for early detection and management of hearing
loss (Joint Committee on Infant Hearing, 2007). General
anesthesia also introduces health risks such as respiratory
and cardiac complications (Jenkins & Baker, 2003).
There are alternatives to general anesthesia for obtaining
threshold-finding ABR results in infants and young
children. For example, several studies have reported on
the efficacy of melatonin as an alternative to sedation
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for ABR testing (Guerlain et al., 2016; Marseglia et al.,
2015; Schmidt, Knief, Deuster, Matulat, & am ZehnhoffDinnesen, 2007) and other procedures in children typically
requiring the use of sedation (Marseglia et al., 2015). The
efficacy of melatonin was assessed in a large sample
of 250 children assessed with both click and tone burst
stimuli in notched noise (Schmidt et al., 2007). Although
the use of melatonin significantly reduced the need for
general anesthesia by more than 80%, thresholds for
a click, and three or more tone burst stimuli were only
obtained in 57% of children assessed with melatonin-aided
sleep (Schmidt et al., 2007). However, success rates were
markedly better for children less than one year of age than
for older children (Schmidt et al., 2007). More recently,
use of melatonin was assessed in 56 children from 1
year to 14.5 years who were administered ABR testing
with a protocol that included only thresholds for click
stimuli (Guerlain et al., 2016). The click-evoked ABR was
completed among 43 patients. In the patients successfully
tested, the mean delay to achieving sleep was 35 minutes
and the mean duration of sleep only 23 minutes (Guerlain
et al., 2016).
Another alternative to sedation use for ABR testing
involves using sophisticated response collection
algorithms which are more robust in the presence of
patient-generated motion artifact (e.g., Kalman adaptive
processing; Cone & Norrix, 2015). Kalman adaptive
averaging has been used to improve the signal to
noise ratio in noisy recordings and has been shown to
reduce the averaging time needed for resolution of ABR
responses by 75% as compared to more traditional
averaging techniques (Chan, Lam, Poon, & Qiu, 1995).
In the presence of motoric activity, Kalman-weighted
averaging coupled with in situ bio-amplifiers results in ABR
threshold estimates that are 6 to 7 dB lower than when
conventional ABR averaging methods are used (Cone
& Norrix, 2015). It was suggested that the methodology
may make it possible to test some infants in an awake
state without the associated added costs and potential
delays inherent with use of sedation or general anesthesia
(Cone & Norrix, 2015). The effectiveness the commercial
application of Kalman-weighted averaging coupled with
in situ bio-amplifiers was undertaken in 103 children who
were administered click and tone burst evoked ABR testing
without use of sedation (Hall, 2010). It was not possible to
record any interpretable ABR results on 6% of the children
(Hall, 2010). Click evoked ABR thresholds were obtained
on 94% of children. However, the instrumentation was less
effective in obtaining thresholds for 500 Hz (24% of Ss),
1000 Hz (36% of Ss), 2000 Hz (40% of Ss), and 4000 Hz
(40% of Ss) for the tone burst stimuli (Hall, 2010).
Use of conscious or moderate sedation is also
an alternative to general anesthesia for achieving
an adequate level of cooperation for ABR testing
(Reynolds, Rogers, Medellin, Guzman, & Watcha,
2016). Dexmedetomidine has been used in recent
years to achieve moderate levels of sedation for ABR
and other procedures (Ambi, Joshi, Ganeshnavar, &

Adarsh, 2012; Reynolds, Rogers, Medellin et al., 2016).
Dexmedetomidine achieves rapid onset of sedation
effects with a relatively short half-life which lends itself
to non-invasive outpatient procedures such as magnetic
resonance imaging (MRI) and ABR studies (Phan &
Nahata, 2008). In addition, intranasal dexmedetomidine
has some potentially beneficial analgesic and anxiolytic
side effects which might be significant for some patients
(Phan & Nahata, 2008). Use of dexmedetomidine was
approved by the Food and Drug Administration for use in
non-intubated adult patients in 2008 and has been used in
pediatric applications for procedures which are minimally
invasive off-label since that time (Shukry & Miller, 2010).
It is not a controlled substance (Drug Enforcement
Administration, 2017). Dexmedetomidine is an anxiolytic
and sedative medication which is used in the intensive
care setting for light to moderate sedation (Phan & Nahata,
2008). It is an agonist of alpha2-adrenergic receptors in
certain parts of the brain and is similar to the medication
clonidine, which is often prescribed in children with
attention deficit hyperactivity disorder (Sallee, Connor, &
Newcorn, 2013). It can provide sedative effects without
risk of respiratory depression, unlike other commonly
used sedatives such as propofol, fentanyl, and midazolam
(Phan & Nahata, 2008). Dexmedetomidine is absorbed
through the olfactory mucosa, allowing for intranasal
administration (Iirola et al., 2011). Dexmedetomidine
does have potential adverse side effects which include
lowered blood pressure and decreased oxygen in tissues
or blood (Cravero, Anderson, & Wolf, 2015). Although
use of dexmedetomidine has been shown to reduce heart
rate and blood pressure, vital signs remain within safe
physiologic limits and no serious adverse effects have
been reported (Surendar, Pandey, Saksena, Kumar, &
Chandra, 2014). Intranasal dexmedetomidine produces
considerably less impact upon respiration than alternative
forms of sedation and is regarded as safer than chloral
hydrate or other alternative drugs used to achieve
conscious sedation (Cozzi, Norbedo, & Barbi, 2017).
Intranasal dexmedetomidine has been used to achieve
moderate levels of sedation for MRI studies (Ambi,
Joshi, Ganeshnavar, & Adarsh, 2012; Zhang et al., 2016)
and for electroencephalogram studies (Baier, Mendez,
Kimm, Velazquez, & Schroeder, 2016) as well as auditory
brainstem response measurements in children (Baier
et al., 2016; Reynolds, Rogers, Capehart, Manyang, &
Watcha, 2016; Reynolds, Rogers, Medellin et al., 2016).
Moderate sedation is an alternative to general anesthesia
which requires less intensive medical supervision
and can be undertaken outside of an operating room
environment. Chloral hydrate was widely used to achieve
moderate sedation for ABR studies but is no longer used
for several reasons. Respiratory depression, vomiting,
and paradoxical hyperactivity are potential side effects of
chloral hydrate sedation (Greenberg, Faerber, & Aspinall,
1991). Complications such as vomiting, hyperactivity,
or rash have been reported in 20.7% of children tested
with chloral hydrate (Avlonitou et al., 2011). Additionally,
chloral hydrate is often administered orally, which requires
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cooperation of the patient to swallow the medication
in order to ensure accurate dosing. There is also a
heightened risk of respiratory compromise with the
possibility of neurologic injury in patients with certain
conditions (e.g., cerebral palsy, obstructive sleep apnea,
hypertrophic tonsils and adenoids, and tracheostomy;
Phan & Nahata, 2008). Finally, chloral hydrate is difficult to
obtain, as the sole remaining pharmaceutical manufacturer
in the United States has ceased production of the
medication (Mason, 2014). Choral hydrate is still in use in
other countries (Valenzuela et al., 2016). However, it has
not been recommended for use in pediatric sedation for
a number of years (Cote, Karl, Notterman, Weinberg, &
McCloskey, 2000). Use of chloral hydrate is now banned
in France and Italy due to evidence of carcinogenicity and
genotoxicity (Cozzi et al., 2017).
In anticipation that chloral hydrate would no longer be
available, a team with representatives from pediatrics,
pediatric anesthesiology, nursing, and pharmacy
considered available medications for moderate sedation
and selected intranasal dexmedetomidine as the
most suitable option for the Kennedy Krieger Institute
(KKI) because of its safety profile, lack of respiratory
depression effects, and ease of administration. Intranasal
dexmedetomidine has been shown to achieve moderate
levels of sedation in significantly less time than chloral
hydrate with no occurrences of hypoxemia (Reynolds,
Rogers, Medellin et al., 2016; Zhang et al., 2016). First
dose success rates for intranasal dexmedetomidine have
been shown to be higher than those achieved previously
in patients sedated with chloral hydrate (Baier et al.,
2016). The injectable formulation of dexmedetomidine
is administered into the nose using an atomizer. This
method of administration has been used safely in
previous investigations evaluating the sedative effects of
dexmedetomidine in children (Baier et al., 2016; Cravero et
al., 2015; Reynolds, Rogers, Medellin et al., 2016). Onset
of sedation is typically about 20 to 30 minutes and lasts 60
to 90 minutes (Reynolds, Rogers, Medellin et al., 2016).
The purpose of the present retrospective study was to
compare the effectiveness of intranasal dexmedetomidine
with chloral hydrate in achieving an adequate state for
the auditory brainstem response testing protocol used at
Kennedy Krieger Institute. Consecutive medical records
were examined with no attempt made to control for subject
variables. This protocol requires obtaining responses to
click stimuli and tone bursts centered at 500, 2000, and
4000 Hz for both ears. The tone bursts were presented
in the background of notched noise. Tympanometry
and measurements of otoacoustic emissions are
also performed. Few studies have investigated the
effectiveness of intranasal dexmedetomidine for sedation
in ABR studies (Reynolds, Rogers, Medellin et al.,
2016). No studies have quantified the effectiveness of
dexmedetomidine for a range of stimulus conditions,
including both click stimuli and frequency specific tone
burst stimuli. Previous studies investigating the efficiency
of intranasal dexmedetomidine in sedation for ABR studies

have included only a single stimulus condition (Baier et al.,
2016; Reynolds, Rogers, Capehart et al., 2016; Reynolds,
Rogers, Medellin et al., 2016). Such data do not permit the
degree, configuration, and etiology of a hearing loss to be
determined. It is important that effectiveness of intranasal
dexmedetomidine be evaluated for a range of stimulus
conditions because the completeness of this data informs
treatment decisions and the need for further evaluation
and/or intervention.
Procedures
This investigation was approved by the Johns Hopkins
Medicine Institutional Review Board. A retrospective
chart review was conducted for patients at Kennedy
Krieger Institute who underwent sedated ABR
testing. Data were available for 64 patients sedated
with intranasal dexmedetomidine and 35 patients
sedated with chloral hydrate. The subjects in the
dexmedetomidine group ranged from 6 months of age
to 10 years and 7 months of age (mean age = 3.30
years). The subjects in the chloral hydrate group ranged
in age from 7 months to 5 years and 11 months (mean
age = 2.80 years). Sedated ABR testing is typically not
performed on children younger than six months because
these children are usually able to sleep without sedation
for the duration of testing. The subjects typically had
multiple diagnoses including speech and language
delay, history of otitis media, behavior disorders,
autism spectrum disorder, ADHD, global developmental
delay, and hypotonia. All subjects were medically
evaluated by a Kennedy Krieger Institute developmental
pediatrician as well as by their own pediatrician to
ensure candidacy for sedation. A sedation referral
form, shown in Table 1, was completed by each child’s
pediatrician prior to scheduling an appointment for a
sedated ABR. Because dexmedetomidine lowers heart
rate and blood pressure, it is contraindicated for use
in children with known bradycardia, hypotension, or
other cardiac problems. When children were screened
for sedation, it was decided that dexmedetomidine
would not be used in children who were taking other
medications that lower heart rate or blood pressure.
Dosing and response to dexmedetomidine may be
affected if children are prescribed other alpha-2
agonists. Guanfacine and clonidine are the two alpha-2
agonists that are commonly prescribed. Guanfacine,
also known as Intuniv, is approved for treatment
of attention deficit hyperactivity disorder (ADHD).
Clonidine can be used for treatment of ADHD and high
blood pressure. Tizanidine is also a related medication.
The protocol at KKI specifies that patients discontinue
these medications for 2 weeks prior to sedation, as
dexmedetomidine will be more effective if patients do
not have tolerance to that class of medications.
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Table 1
Pre-Sedation Referral Form
Name:

DOB:

KKI#:

AEP DATE:

The above named patient has been referred for sedated AEP testing. Intranasal Dexmedetomidine will be administered.
Medical Problem List

Allergies (or sensitivities,
especially to meds)

Medications

Past Surgeries

Any prior complications of anesthesia or sedation? [ ] yes [ ] no
Pertinent Past Medical History (elaborate on any Yes responses):
Yes No History of:

Yes No History of:

History of:
Premature birth

Obstructive sleep apnea

Congenital anomaly

Apnea

Aspiration

Anemia

ENT Problems

Asthma

History of transfusion

Feeding/Swallowing problems

Other pulmonary disease

Other blood disorder

Gastroesophageal reflux

Congenital heart disease

Seizures/epilepsy

Frequent vomiting

Need for SBE prophylaxis

Hydrocephalus/Shunt

Liver disease

Arrhythmia

Cerebral palsy

Kidney disease

Other heart disease

Other neurologic problem

Yes No

Additional Info:
Physical Exam:

Normal (N) / Abnormal (A)

Abnormal (describe)

HEENT

Abdomen

Lungs

Other

Cardiovascular

Weight:

Height:

I evaluated the above patient on
and find the patient to be in his/her usual state of health and find no
contraindications to doing AEP testing under moderate sedation.
Printed Name

Provider Signature

Date/Time

Note. AEP = Auditory Evoked Potential; ENT = Ear, Nose, and Throat; HEENT = Head, Ear, Eyes, Nose, and Throat; SBE = Subacute
Bacterial Endocarditis Prophylaxis
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Dexmedetomidine is administered through intranasal
administration by contact with the olfactory mucosa (Iirola
et al., 2011). This was achieved with use of a tuberculin
syringe with an atomizer device. Guidelines promulgated
by the Committee on Drugs of the American Academy
of Pediatrics pertaining to dietary precautions, as well
as monitoring and management of pediatric patients for
conscious sedation were followed (American Academy
of Pediatrics, 1992). Patients received an examination
from a developmental pediatrician and a health history
was taken along with a baseline weight and vital signs.
Due to the possible effects of decreased blood pressure
and pulse, the patients were monitored by a nurse
throughout the procedure. Blood oxygen saturation
was measured by continuous pulse oximetry. Blood
pressure measurements were taken every 15 minutes.
The available dosing of dexmedetomidine at KKI was in
a concentration of 100mcg/1cc. The dosing was usually
split between each nostril to decrease runoff and maximize
absorptive tissue area. The ideal volume per nostril is
0.2–0.3cc and maximum recommended dose is 0.5–1cc
per nostril (Barclay & Lie, 2010). When administering
small doses to younger patients, it was necessary to dilute
dexmedetomidine to a concentration of 50mcg/1cc to allow
adequate volume for intranasal use. On the day following
the appointment, a telephone call was placed to each
patient’s parent/guardian to inquire about recovery and any
adverse effects. Based on continued evaluation of patient
response intranasal dexmedetomidine at KKI, the current
dosing protocol is to give 2 mcg/kg for the initial dose.
Previous research provides evidence that a 2 mcg/kg dose
is effective for sedation in pediatric populations (Yuen et
al., 2012). If the patient is not sufficiently sedated by 25
minutes after the initial dose, an additional 1 mcg/kg dose
of intranasal dexmedetomidine is given. A third dose of 1
mcg/kg is given if the patient remains awake 25 minutes
after the second dose. Dosing remains individualized
but this protocol has provided consistent results for the
majority of our sedated auditory evoked potential and
electroencephalogram procedures. The dosing for chloral
hydrate was 75 mg/kg. When vomiting occurred with
chloral hydrate administration, re-administration of the
medication was required. In some such cases, sedation
was ineffective.
After ensuring the patient had reached an adequate state
for testing, ABR data were collected using an Intelligent
Hearing System’s (IHS) Smart Evoked Potential System.
The skin was prepped using NuPrep solution and
standard EEG disk electrodes were affixed to the following
locations: Fpz (ground), Fz (non-inverting), A1 and A2
(inverting for ipsilateral and contralateral ear). Click stimuli
and tone burst stimuli centered at 500, 2000, and 4000 Hz
were presented to each ear via insert earphones. Notched
noise was used for the tone burst stimuli. If any degree of
hearing loss was present, testing by bone conduction was
completed with the delivery of appropriate contralateral
masking noise. Tympanometry and measurements of
otoacoustic emissions were also performed following
ABR testing.

Results
Complete audiological data was defined as having
obtained thresholds for click stimuli and for tone burst
stimuli centered at 500, 2000, and 4000 Hz for both
the left and the right ear. Complete audiological data
were obtained on 92.2% of patients sedated with
dexmedetomidine. Complete audiological data were
obtained on 91% of patients sedated with choral
hydrate. A chi-square analysis revealed that there was
no significant difference in outcome between the two
forms of sedation (χ2(1, N = 99) = 0.0175, p = 0.89).
Complete data were obtained for at least one ear on all
patients.
Table 2
Participant Demographics
Sedation Type

Effective

Not effective

Dexmedetomidine
(n = 64)

92%
(n = 59)

8%
(n = 5)

Sedation Type:
Chloral Hydrate
(n = 35)

91%
(n = 32)

9%
(n = 3)

Most of the children required two (50%) or three doses
(20%) of dexmedetomidine. Only 30% of patients
sedated with a single dose. The average times before
sedation were 25 minutes, 39.4 minutes, and 57.5
minutes for patients requiring 1, 2 or 3 doses of
dexmedetomidine respectively.
The mean age for patients sedated with
dexmedetomidine who were adequately sedated with
only one dose was 3 years. The range of ages of
children receiving a single dose was 6 months to 10.5
years. The mean age for those receiving more than 1
dose was 4.4 years, with a range of 9 months to 10.6
years. The mean total examination time across all
participants who received dexmedetomidine was 53.1
minutes. No patients in the dexmedetomidine group
required supplemental oxygen. All patients returned
to baseline functioning and were discharged on the
same day as the procedure. No patients receiving
dexmedetomidine experienced nausea or vomiting that
was either observed or reported after discharge.
Discussion
The results of this investigation indicate that intranasal
dexmedetomidine is as effective as chloral hydrate
in achieving moderate levels of sedation for ABR
testing. No sentinel events occurred due to the use of
dexmedetomidine. None of the adverse side effects
associated with chloral hydrate including vomiting,
hyperactivity, or respiratory depression occurred during
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the use of intranasal dexmedetomidine. Intranasal
dexmedetomidine was noted by all members of the
team to be far easier to administer than oral chloral
hydrate. Intranasal administration requires minimal
cooperation from the patient. A team member or family
member gently tilts the patient’s head posteriorly and
immobilizes the head while the nasal spray is being
administered. The patient remains in this position for
approximately 20 seconds and can then resume normal
activities. In contrast, administration of chloral hydrate
required staff to induce patients to swallow an ill-tasting
medication which was for some patients difficult to
achieve without uncertain amounts of the medication
being spit out or vomited. This study supports previous
studies suggesting that intranasal dexmedetomidine is
an appropriate alternative to chloral hydrate or general
anesthesia for ABR testing for most patients (Baier et
al., 2016; Reynolds, Rogers, Medellin et al., 2016).
The effectiveness of dexmedetomidine appears to be
superior to that of alternatives such as administration
of melatonin (Schmidt et al., 2007) or use of Kalman
averaging (Hall, 2010) which previous studies have
shown to be less effective than results achieved in the
present study.
Several limitations of the present investigation were
noted. The retrospective design of the investigation did
not allow for variables such as patient age, the presence
of health conditions, or time of testing to be controlled or
systematically examined. Additionally, the participants in
this investigation were limited to the patients who chose
to seek care at KKI. Use of dexmedetomidine requires
medical monitoring and continuous physiological
monitoring with the attendant expense just as when
using chloral hydrate. Further investigations should be
completed to include larger sample sizes and diverse
populations. As noted earlier, there are alternatives to
moderate sedation or general anesthesia for obtaining
threshold-finding ABR results in infants and young
children. For example, several studies have reported on
the efficacy of melatonin as an alternative to sedation
for ABR testing with few adverse side effects (Guerlain
et al., 2016; Marseglia et al., 2015; Schmidt et al.,
2007). Future research comparing the effectiveness and
safety of melatonin to dexmedetomidine for obtaining
ABR measurements should be completed to determine
if either medication is more effective. Additionally,
Kalman adaptive averaging has been used to improve
the signal to noise ratio in noisy recordings and has
been shown to reduce the averaging time needed for
resolution of ABR responses by 75% as compared to
more traditional averaging techniques (Chan et al.,
1995). Incorporating the use of this technology may
improve the effectiveness of sedation medication by
shortening the length of test time and allowing a greater
amount of patient movement. Future investigations
could evaluate the effectiveness of dexmedetomidine
and/or other sedation medications while incorporating
this signal averaging technology.

Conclusions
Measurement of ABRs is an important tool for the
delineation of hearing status, as the ABR allows the
auditory status of infants and children to be assessed
when other methods are inappropriate or unsuccessful.
Although sedation is commonly used for ABR testing,
no medication has yet replaced chloral hydrate as the
clinical standard since its large-scale production was
ceased. The results of this study suggest that intranasal
dexmedetomidine is an acceptable form of sedation for
ABR testing in pediatric patients. Complete audiological
data was achieved in 92% of patients. This was
accomplished without any of the patients experiencing
breathing difficulty, vomiting, or other sentinel effects
during or after the procedure. Dexmedetomidine
demonstrated similar rates of effectiveness as chloral
hydrate with fewer side effects. This study contributes
to the body of literature supporting the use of
dexmedetomidine for clinical use in facilities performing
sedated ABR measurements.
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